Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML).
The Details:
The company presented data on Saturday which showed prexigebersen to be well-tolerated and has demonstrated efficacy results in two reporting cohorts including newly diagnosed AML patients and refractory/relapsed AML patients, both of which exceeded outcomes with frontline therapy.
Related News: What's Going On With Snowflake Stock?
"We were honored to have our data selected for oral presentation at ASCO as it underscores not only the quality of our data, but also highlights the continued unmet need for these most vulnerable cancer patients," said Peter Nielsen, CEO of Bio-Path.
"We continue to advance this important study confident that prexigebersen can make a difference in the lives of these patients for whom there are limited treatment options."
Bio-Path shares are moving on heavy trading volume on Monday following the announcement. According to data from Benzinga Pro, more than 34.375 million shares have already been traded in the session, compared to the stock's float of only 1.655 million shares.
Is BPTH A Good Stock To Buy?
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Bio-Path's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Bio-Path does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 13.76%, you'll need to buy a share of Neuberger Berman by June 17, 2024. Once done, you can expect to receive a nominal payout of $0.09 on June 28, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Bio-Path Hldgs will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
BPTH Price Action: According to Benzinga Pro, Bio-Path shares are up 80% at $3.71 at the time of publication Monday.
Image: Shutterstock